| scholarly article | Q13442814 |
| P50 | author | Elizabeth Streicher | Q30111637 |
| Robin M. Warren | Q42425682 | ||
| Marisa Klopper | Q55979001 | ||
| Borna Müller | Q81698646 | ||
| P2093 | author name string | Gerrit Coetzee | |
| Cindy Hayes | |||
| Ebrahim Hoosain | |||
| Paul David van Helden | |||
| Mamisa Chabula-Nxiweni | |||
| André Phillip Trollip | |||
| Frederick Adriaan Sirgel | |||
| Nicolaas Claudius Gey van Pittius | |||
| Thomas Calldo Victor | |||
| P2860 | cites work | Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa | Q28272340 |
| Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa | Q28471774 | ||
| Tuberculosis drug resistance mutation database | Q28474770 | ||
| Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa | Q28476143 | ||
| Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology | Q29547284 | ||
| Population structure of multi- and extensively drug-resistant Mycobacterium tuberculosis strains in South Africa | Q34101580 | ||
| Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa | Q34216252 | ||
| Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. | Q34974467 | ||
| Canadian multicenter laboratory study for standardized second-line antimicrobial susceptibility testing of Mycobacterium tuberculosis | Q35599028 | ||
| Spoligotype signatures in the Mycobacterium tuberculosis complex. | Q35690253 | ||
| Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence | Q36539733 | ||
| Multiplex PCR assay specific for the multidrug-resistant strain W of Mycobacterium tuberculosis | Q37092846 | ||
| Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens | Q37214096 | ||
| Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa | Q37917035 | ||
| The competitive cost of antibiotic resistance in Mycobacterium tuberculosis | Q40311130 | ||
| Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study | Q43058124 | ||
| Safe Mycobacterium tuberculosis DNA extraction method that does not compromise integrity | Q43159340 | ||
| Drug-resistant tuberculosis epidemic in the Western Cape driven by a virulent Beijing genotype strain. | Q43748661 | ||
| Patients with active tuberculosis often have different strains in the same sputum specimen | Q44209917 | ||
| An outbreak of drug-resistant tuberculosis caused by a Beijing strain in the western Cape, South Africa | Q44319103 | ||
| Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients | Q44745196 | ||
| Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. | Q45126969 | ||
| Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa | Q46458797 | ||
| inhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa? | Q46600027 | ||
| Classification of drug-resistant tuberculosis in an epidemic area | Q46669080 | ||
| Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. | Q46824322 | ||
| XDR tuberculosis: an indicator of public-health negligence | Q46834002 | ||
| Phylogenetic reconstruction within Mycobacterium tuberculosis Beijing genotype in northwestern Russia | Q47409707 | ||
| Mutations in the rrs A1401G Gene and Phenotypic Resistance to Amikacin and Capreomycin in Mycobacterium tuberculosis | Q57385370 | ||
| The treatment of pulmonary tuberculosis | Q78623081 | ||
| Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa | Q81569357 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Totally drug-resistant tuberculosis | Q7828253 |
| South Africa | Q258 | ||
| tuberculosis | Q12204 | ||
| P304 | page(s) | 449-455 | |
| P577 | publication date | 2013-03-01 | |
| P1433 | published in | Emerging Infectious Diseases | Q5235761 |
| P1476 | title | Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa | |
| P478 | volume | 19 |
| Q35890502 | A Novel Molecular Strategy for Surveillance of Multidrug Resistant Tuberculosis in High Burden Settings |
| Q35988987 | A Subgroup of Latently Mycobacterium tuberculosis Infected Individuals Is Characterized by Consistently Elevated IgA Responses to Several Mycobacterial Antigens. |
| Q89514290 | A landscape of genomic alterations at the root of a near-untreatable tuberculosis epidemic |
| Q35076966 | A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections. |
| Q41607614 | Added value of whole-genome sequencing for management of highly drug-resistant TB. |
| Q35538913 | Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study |
| Q39354581 | Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds |
| Q39062989 | Antibiotic Resistant Superbugs: Assessment of the Interrelationship of Occurrence in Clinical Settings and Environmental Niches. |
| Q91876701 | Antibiotic resistance and R&D failure: The need for near real-time disaster research |
| Q40559656 | Blockade of the Kv1.3 K+ Channel Enhances BCG Vaccine Efficacy by Expanding Central Memory T Lymphocytes |
| Q30251933 | Challenges in the clinical assessment of novel tuberculosis drugs. |
| Q40447683 | Characterization of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone as a novel inhibitor of methionine aminopeptidases from Mycobacterium tuberculosis. |
| Q47139099 | Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa |
| Q90161311 | Continuity of care for TB patients at a South African hospital: A qualitative participatory study of the experiences of hospital staff |
| Q26777926 | Data for action: collection and use of local data to end tuberculosis |
| Q41992338 | Design, Synthesis and Characterization of N-oxide-containing Heterocycles with In vivo Sterilizing Antitubercular Activity. |
| Q53764026 | Diagnostic performance of automated liquid culture and molecular line probe assay in smear-negative pulmonary tuberculosis. |
| Q28550914 | Diversity of Mycobacterium tuberculosis across Evolutionary Scales |
| Q64234748 | Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study |
| Q40428516 | Effect of common and experimental anti-tuberculosis treatments on Mycobacterium tuberculosis growing as biofilms |
| Q26771997 | Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations? |
| Q36822433 | Epidemiological Trends of Drug-Resistant Tuberculosis in China From 2007 to 2014: A Retrospective Study |
| Q30202269 | Ethics for pandemics beyond influenza: Ebola, drug-resistant tuberculosis, and anticipating future ethical challenges in pandemic preparedness and response |
| Q34922635 | Evaluation of pyrosequencing for detecting extensively drug-resistant Mycobacterium tuberculosis among clinical isolates from four high-burden countries |
| Q34466858 | Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient |
| Q35544538 | Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage |
| Q40413692 | Formulation development and optimization of Lamivudine 300 mg and Tenofovir Disoproxil Fumarate (TDF) 300 mg FDC tablets by D-optimal mixture design. |
| Q60949889 | Genome Sequences and Comparative Analysis of Two Extended-Spectrum Extensively-Drug Resistant Strains |
| Q38198853 | Genomic insights into tuberculosis |
| Q54411682 | Genotypes of Mycobacterium tuberculosis isolates in rural China: using MIRU-VNTR and spoligotyping methods. |
| Q33926262 | Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis |
| Q64928785 | Government policy interventions to reduce human antimicrobial use: A systematic review and evidence map. |
| Q28546682 | High frequency of resistance, lack of clinical benefit, and poor outcomes in capreomycin treated South African patients with extensively drug-resistant tuberculosis |
| Q36912028 | How the threat of antibiotic apocalypse helped a pharmacist find her voice |
| Q40333807 | Identification of the anti-mycobacterial functional properties of piperidinol derivatives. |
| Q40332311 | Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study |
| Q56828266 | Insights into the processes that drive the evolution of drug resistance in Mycobacterium tuberculosis |
| Q39446322 | Lifestyle, attitudes and needs of uncured XDR-TB patients living in the communities of South Africa: a qualitative study |
| Q39355934 | Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study |
| Q40661732 | LppM impact on the colonization of macrophages by Mycobacterium tuberculosis |
| Q35778015 | Metabolic modeling predicts metabolite changes in Mycobacterium tuberculosis |
| Q39461808 | Micrococcin P1 - A bactericidal thiopeptide active against Mycobacterium tuberculosis |
| Q37621713 | Minimal diversity of drug-resistant Mycobacterium tuberculosis strains, South Africa |
| Q89976320 | MmpS5-MmpL5 Transporters Provide Mycobacterium smegmatis Resistance to imidazo[1,2-b][1,2,4,5]tetrazines |
| Q36173979 | Molecular Epidemiological Interpretation of the Epidemic of Extensively Drug-Resistant Tuberculosis in South Africa. |
| Q55091455 | Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains. |
| Q39583213 | Molecular design, structures, and activity of antimicrobial peptide-mimetic polymers |
| Q38258834 | Mycobacterium tuberculosis evolutionary pathogenesis and its putative impact on drug development |
| Q33854476 | Nanoparticle-Formulated Curcumin Prevents Posttherapeutic Disease Reactivation and Reinfection with Mycobacterium tuberculosis following Isoniazid Therapy |
| Q33600161 | New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria |
| Q26751463 | New agents for the treatment of drug-resistant Mycobacterium tuberculosis |
| Q47594312 | New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development |
| Q47627527 | Pharmacokinetic studies of a three-component complex that repurposes the front line antibiotic isoniazid against Mycobacterium tuberculosis |
| Q28818217 | Pipeline of drugs for related diseases: tuberculosis |
| Q30234388 | Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified? |
| Q42218454 | Prediction of XDR/pre-XDR tuberculosis by genetic mutations among MDR cases from a hospital in Shandong, China |
| Q35769140 | Prevalence of Tuberculosis, Drug Susceptibility Testing, and Genotyping of Mycobacterial Isolates from Pulmonary Tuberculosis Patients in Dessie, Ethiopia |
| Q52568989 | Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey. |
| Q37133281 | Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosis |
| Q92322181 | Primary bacillary resistance in multidrug-resistant tuberculosis and predictive factors associated with cure at a referral center in São Paulo, Brazil |
| Q28535594 | Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa |
| Q30235139 | Relapse, re-infection and mixed infections in tuberculosis disease |
| Q28074085 | Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective |
| Q34604407 | Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay |
| Q40275920 | Strategies for halting the rise of multidrug resistant TB epidemics: assessing the effect of early case detection and isolation |
| Q35039469 | Structure and activity of lobophorins from a turrid mollusk-associated Streptomyces sp |
| Q35039936 | Synthesis and antimicrobial activity of α-aminoboronic-containing peptidomimetics |
| Q58694590 | Systematic review in South Africa reveals antibiotic resistance genes shared between clinical and environmental settings |
| Q34671468 | Temporal dynamics of Mycobacterium tuberculosis genotypes in New South Wales, Australia |
| Q30235074 | The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis |
| Q45346915 | The need for improved tuberculosis control. |
| Q55545454 | The occurrence and frequency of genomic mutations that mediate Isoniazid and Rifampicin resistance in Mycobacterium tuberculosis isolates from untreated pulmonary Tuberculosis cases in urban Blantyre, Malawi. |
| Q36781680 | The totally drug resistant tuberculosis (TDR-TB) |
| Q37335803 | Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners |
| Q38210265 | Totally drug-resistant tuberculosis and adjunct therapies. |
| Q36094210 | Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done |
| Q64134549 | Transmission of drug-resistant tuberculosis in HIV-endemic settings |
| Q35868609 | Transmitted Extended-Spectrum Extensively Drug-Resistant Tuberculosis in Beijing, China, with Discordant Whole-Genome Sequencing Analysis Results |
| Q34480272 | Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. |
| Q58731377 | Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis |
| Q64117158 | Whole genome sequencing for drug resistance determination in Mycobacterium tuberculosis |
| Q36355339 | Whole genome sequencing identifies circulating Beijing-lineage Mycobacterium tuberculosis strains in Guatemala and an associated urban outbreak |
| Q30300187 | Whole-genome sequencing in outbreak analysis |
| Q37524183 | Why test for tuberculosis? A qualitative study from South Africa |
Search more.